top of page

KRAS Cancer News & Updates



What Is ASCO Conference—And Should Cancer Patients Care?
💡 Why It Matters to Patients:
Even if you’re not in the room, what happens at ASCO can shape your treatment options—now and in the future. KRAS-driven cancers (lung, colon, pancreatic, and rare cancers) are a major area of focus at ASCO. knowing what’s coming can help you:
-Ask better questions -
-Stay ahead of the curve -
-Find hope in options you didn’t know existed- Gen-Me Medicine—where cancer care is about matching the right treatment to your unique molecular fingerpri

Terri Conneran KRAS Kickers
Jun 10


Precision Medicine has Empowered Cancer Patients
One of the patient voices from this documentary is Terri Conneran: Empowering the Patients For Precision Cancer Advocacy In the documentary, powerful stories from patients, industry experts, and healthcare providers about how precision medicine has empowered their healthcare decisions, providing renewed hope .


Why AML Treatments Don’t Always Work—and What This Study Reveals About KRAS, NPM1, and Monocytic Resistance
By KRAS Kickers – Cancer Knowledge + Research + Advocacy = Survivorship 📅 May 2025 | 🧬 Published in Blood Cancer Discovery 🔬...

Terri Conneran KRAS Kickers
May 22


Rare Pancreas cancer FGFR + KRAS trial - comes to you
Rare Pancreatic cancer trial comes to you! FGFR + KRAS

Terri Conneran KRAS Kickers
May 19


Lung & Pancreatic cancer Patient Knowledge of Research
KRAS Kickers is a cancer patient-led nonprofit organization that shares Knowledge of publicly available Research to empower patients and caregivers to Advocate for Survivorship.
Our goal to kick cancer's KRAS!


Unveiling impacts: A quality of life survey for individuals with a history or diagnosis of cancer.
https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.16_suppl.e23179 Abstract Journal of Clinical Oncology Volume 42, Number 16_suppl June...

Terri Conneran KRAS Kickers
Apr 25


Essential Guide to Cancer Biomarkers For Cancer Patients
Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus.
Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference.
Biomarkers provide the insights as to what is driving the cancer.

Terri Conneran KRAS Kickers
Apr 22


NEW combination trial arm of RMC-9805 plus RMC-6236
Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...
fireflyannf
Apr 7


Black Diamond trial of BDTX-4933
A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers Brief Summary: "BDTX-4933-101 is a...
fireflyannf
Apr 7


KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
" Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with...
fireflyannf
Apr 7
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
PHASE 1 trial: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS At MD...
fireflyannf
Apr 7


A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors
Phase 1 trial, 230 patients Trial opened April 2024 in Australia Expanded to US Locations in September 2024  “ Brief Summary This is a...
fireflyannf
Apr 7


PROSPER trial for KRAS G12C mutations
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)  Phase 1/2 - 403 patients to enroll Opened in...
fireflyannf
Apr 7


Study of IK-595 in RAS- or RAF-altered Advanced Tumors
"This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK),...
fireflyannf
Apr 7


Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS
Phase 1 trial Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumors Enrollment into...
fireflyannf
Apr 7


Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
"Brief Summary Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as...
fireflyannf
Apr 7


BREAKER-101 trial - Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors
“First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in...
fireflyannf
Apr 7


Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic, colorectal and non-small cell lung cancer
ESMO24 abstract 608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in...
fireflyannf
Mar 30


KICKING KRAS LUNG CANCER!
Upstage Lung Cancer heard the power of hope to kick cancer from Terri Conneran

Terri Conneran KRAS Kickers
Dec 19, 2024


SPARK study: Studying Pathways of Resistance in KRAS-12C driven Cancers
Brief Summary “Up to 250 patients from anywhere in the United States can remotely consent and participate  to have plasma drawn locally...
fireflyannf
Oct 13, 2024
Cancer Treatment & Clinical Trial Eligibility: What Patients Need to Know
Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type.
6 things that matter...
What Every Cancer Patient Should Know About Today’s Treatment Options
..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.
What Is ASCO Conference—And Should Cancer Patients Care?
💡 Why It Matters to Patients:
Even if you’re not in the room, what happens at ASCO can shape your treatment options—now and in the future. KRAS-driven cancers (lung, colon, pancreatic, and rare cancers) are a major area of focus at ASCO. knowing what’s coming can help you:
-Ask better questions -
-Stay ahead of the curve -
-Find hope in options you didn’t know existed- Gen-Me Medicine—where cancer care is about matching the right treatment to your unique molecular fingerpri
bottom of page